252 related articles for article (PubMed ID: 24622416)
1. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE; Gottlieb PA; Rigby MR; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; Ding L; Bluestone JA; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):306-16. PubMed ID: 24622416
[TBL] [Abstract][Full Text] [Related]
2. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
Gitelman SE; Gottlieb PA; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Harris KM; Kanaparthi S; Phippard D; Ding L; Bluestone JA; Ehlers MR;
Diabetologia; 2016 Jun; 59(6):1153-61. PubMed ID: 27053235
[TBL] [Abstract][Full Text] [Related]
3. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Gitelman SE; Bundy BN; Ferrannini E; Lim N; Blanchfield JL; DiMeglio LA; Felner EI; Gaglia JL; Gottlieb PA; Long SA; Mari A; Mirmira RG; Raskin P; Sanda S; Tsalikian E; Wentworth JM; Willi SM; Krischer JP; Bluestone JA;
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):502-514. PubMed ID: 34214479
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
[TBL] [Abstract][Full Text] [Related]
5. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR; DiMeglio LA; Rendell MS; Felner EI; Dostou JM; Gitelman SE; Patel CM; Griffin KJ; Tsalikian E; Gottlieb PA; Greenbaum CJ; Sherry NA; Moore WV; Monzavi R; Willi SM; Raskin P; Moran A; Russell WE; Pinckney A; Keyes-Elstein L; Howell M; Aggarwal S; Lim N; Phippard D; Nepom GT; McNamara J; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):284-94. PubMed ID: 24622414
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Griffin KJ; Thompson PA; Gottschalk M; Kyllo JH; Rabinovitch A
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):710-8. PubMed ID: 24997559
[TBL] [Abstract][Full Text] [Related]
7. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Perry DJ; Schultz AR; Hulme MA; Shuster JJ; Zou B; Wasserfall CH; Posgai AL; Mathews CE; Brusko TM; Atkinson MA; Schatz DA
Diabetes; 2016 Dec; 65(12):3765-3775. PubMed ID: 27669730
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA
Haller MJ; Long SA; Blanchfield JL; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Geyer SM; Warnock MV; Miller JL; Atkinson MA; Becker DJ; Baidal DA; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell WE; Wilson DM; Greenbaum CJ;
Diabetes; 2019 Jun; 68(6):1267-1276. PubMed ID: 30967424
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
10. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Wilhelm-Benartzi CS; Miller SE; Bruggraber S; Picton D; Wilson M; Gatley K; Chhabra A; Marcovecchio ML; Hendriks AEJ; Morobé H; Chmura PJ; Bond S; Aschemeier-Fuchs B; Knip M; Tree T; Overbergh L; Pall J; Arnaud O; Haller MJ; Nitsche A; Schulte AM; Mathieu C; Mander A; Dunger D
BMJ Open; 2021 Dec; 11(12):e053669. PubMed ID: 34876434
[TBL] [Abstract][Full Text] [Related]
11. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Orban T; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Marks JB; Monzavi R; Moran A; Raskin P; Rodriguez H; Russell WE; Schatz D; Wherrett D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9789):412-9. PubMed ID: 21719096
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA
Haller MJ; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Miller JL; Atkinson MA; Becker DJ; Baidal D; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell W; Wilson DM; Greenbaum CJ;
Diabetes Care; 2018 Sep; 41(9):1917-1925. PubMed ID: 30012675
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Haller MJ; Gitelman SE; Gottlieb PA; Michels AW; Rosenthal SM; Shuster JJ; Zou B; Brusko TM; Hulme MA; Wasserfall CH; Mathews CE; Atkinson MA; Schatz DA
J Clin Invest; 2015 Jan; 125(1):448-55. PubMed ID: 25500887
[TBL] [Abstract][Full Text] [Related]
14. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A; Bensimon G; Payan CA; Jacqueminet S; Bourron O; Nicolas N; Fonfrede M; Rosenzwajg M; Bernard C; Klatzmann D
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):295-305. PubMed ID: 24622415
[TBL] [Abstract][Full Text] [Related]
15. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.
Carlsson PO; Espes D; Sisay S; Davies LC; Smith CIE; Svahn MG
Diabetologia; 2023 Aug; 66(8):1431-1441. PubMed ID: 37221247
[TBL] [Abstract][Full Text] [Related]
16. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Oncol; 2016 Feb; 17(2):164-173. PubMed ID: 26723083
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.
Cadavid D; Balcer L; Galetta S; Aktas O; Ziemssen T; Vanopdenbosch L; Frederiksen J; Skeen M; Jaffe GJ; Butzkueven H; Ziemssen F; Massacesi L; Chai Y; Xu L; Freeman S;
Lancet Neurol; 2017 Mar; 16(3):189-199. PubMed ID: 28229892
[TBL] [Abstract][Full Text] [Related]
20. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
